Two Houston-area companies are joining forces. Photo via Getty Images

A private-equity backed firm has acquired a Houston tech company. The combined entity will enhance logistics for the drug industry.

ToxStrategies, headquartered in Katy, announced the acquisition of Houston-based Modality Solutions this week. ToxStrategies, a portfolio company of Pennsylvania-based Renovus Capital, did not disclose the terms of the deal.

Modality Solutions, founded in 2011 by Gary Hutchinson and Dan Littlefield, focuses on optimized "biopharmaceutical cold chain for novel, fragile, and controlled-temperature medical therapies," per a news release. The company also developed technologies for shipping validation testing. With the acquisition, Hutchison and Littlefield will continue leading Modality as a division of ToxStrategies.

"We are thrilled to become part of the ToxStrategies platform," Hutchinson says in the release. "The combination of our capabilities will provide continued growth opportunities by allowing us to engage with a broader client base, as well as with additional segments of the drug development life cycle than before."

The two Houston-area companies will combine platforms and customers, which include pharmaceutical and biotech clients who need Modality's platform for transporting and storing the increasing amount of therapies that have become more sensitive to changes in temperature.

"The partnership between ToxStrategies and Modality is an ideal strategic fit," says Laurie Couture Haws, president of ToxStrategies, in the release. "Our centralized platform will allow us to cross leverage expertise to better serve our clients across life sciences sectors."

Last November, Renovus Capital Partners backed ToxStrategies partnered with the goal of growing the company's customer base. Renovus manages over $1 billion distributed across its three sector-focused funds. Its current portfolio consists of around 25 businesses based in the United States and specializing in education and training, health care services, technology services, and professional services.

"ToxStrategies has benefitted from being one of several Renovus portfolio companies in the life sciences industry, giving it access to a vast network of relationships, capabilities, and industry expertise," Jesse Serventi, a founding partner at Renovus Capital Partners, says in the release. "We are confident that this acquisition will further enhance ToxStrategies' capabilities as a leading life sciences consultant and create numerous growth opportunities for the company."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.